Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
Respiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and severe infection results in hospitalization with accompanying morbidity and mortality. Palivizumab has been available for prophylaxis for the past 15 years. Prospective data on patients who received palivizumab...
Saved in:
| Main Authors: | Bosco Paes, Ian Mitchell, Abby Li, Tetsuhiro Harimoto, Krista L. Lanctôt |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/917068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice
by: Bosco A Paes, et al.
Published: (2011-01-01) -
Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
by: Andreea Calomfirescu-Avramescu, et al.
Published: (2025-02-01) -
The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma
by: Hannah Ora Hasson, et al.
Published: (2024-11-01) -
Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro
by: Envera Lekic, et al.
Published: (2024-05-01) -
Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply
by: Mehmet Yekta Oncel, et al.
Published: (2013-04-01)